Could Dividend Champions BAE Systems plc, Vodafone Group Plc And AstraZeneca Also Grow By 50%?

Can Vodafone Group Plc (LON: VOD), AstraZeneca Plc (LON: AZN) and BAE Systems Plc (LON: BA) break the mould to provide income and growth?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Shares paying high dividends are normally thought of as low-growth businesses, but could BAE Systems (LSE: BA), Vodafone (LSE: VOD) and AstraZeneca (LSE: AZN) reward shareholders with dividends paying over 4% and appreciate in value by 50% or more?

Winning bet?

BAE shareholders will welcome with open arms the increasing defence budgets in the UK, US, and Saudi Arabia, which together account for over 75% of sales. Due to these increased budgets, BAE may finally reverse five straight years of declining revenues when full-year results are announced next week. During this rebuilding phase management did well to cut costs and increase margins, which allowed earnings per share to remain level from 2010 to 2015 even as revenue fell 25%.

With major business lines much more profitable than they were prior to 2010 and year-on-year revenue finally due to increase, BAE shares could be in for significant upward rerating. Trading at a forward price/earnings multiple of 11.7, there’s room for the shares to grow to reach the levels of major US competitors Boeing and Lockheed Martin, which trade at 14 and 18 times earnings, respectively. This growth potential may not reach a full 50% over the medium term, but with a healthy 4.1% yielding dividend and better days ahead I believe BAE could be a winning bet for income investors.

Should you invest £1,000 in NatWest Group right now?

When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets. And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if NatWest Group made the list?

See the 6 stocks

One to watch

Vodafone’s £20bn infrastructure investment programme, Project Spring, is finally coming to a close this year and has already begun to bear fruit for the mobile phone operator. 4G coverage has expanded from 32% to 80% of Europeans, opening up wide swathes of the continent to Vodafone’s highly profitable data packages.

Analysts are forecasting the possibility of 5% annual organic growth over the next five years. When combined with substantially lower capital expenditure, this is forecast to increase earnings by 19% next year alone. Furthermore, the 5.3% yielding dividend is now covered by earnings and holds the potential to rise alongside profits over the medium term. The bad news for intrigued investors is that much of this growth is baked into share prices already as they’re trading at 34 times projected 2017 earnings. Given current valuations, I don’t foresee the shares increasing in value by 50% over the medium term although Vodafone is still a share to watch.

Patent problems

Drug maker AstraZeneca was knocked back last week on poor guidance for 2016 after blockbuster cholesterol drug Crestor’s patent expired. With heartburn treatment Nexium losing its own patent later this year, AstraZeneca was forced to go on a $10bn buying spree last year to restock its drug pipeline. While the long-term prospects may be very good for AstraZeneca, as management is increasing R&D spending as well as M&A, I believe there will be further pain in the short term for prices.

It’s the nature of the pharmaceuticals industry that drugs take many years to develop before coming to market, and it could be years before AstraZeneca finds a replacement for Nexium and Crestor, which provided more than 35% of revenues last year. Share prices have been mostly flat for the past two years, allowing the P/E ratio to settle at a relatively attractive 15 times forward earnings. Shares may not skyrocket 50% anytime soon, but offer a 4.2% yield and are worth following over the next few years as more drugs go to trial.

Should you buy NatWest Group now?

Don’t make any big decisions yet.

Because Mark Rogers — The Motley Fool UK’s Director of Investing — has revealed 5 Shares for the Future of Energy.

And he believes they could bring spectacular returns over the next decade.

Since the war in Ukraine, nations everywhere are scrambling for energy independence, he says. Meanwhile, they’re hellbent on achieving net zero emissions. No guarantees, but history shows...

When such enormous changes hit a big industry, informed investors can potentially get rich.

So, with his new report, Mark’s aiming to put more investors in this enviable position.

Click the button below to find out how you can get your hands on the full report now, and as a thank you for your interest, we’ll send you one of the five picks — absolutely free!

Grab your FREE Energy recommendation now

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Ian Pierce has no position in any shares mentioned. The Motley Fool UK has recommended AstraZeneca. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

Like buying £1 for 51p

This seems ridiculous, but we almost never see shares looking this cheap. Yet this recent ‘Best Buy Now’ has a price/book ratio of 0.51. In plain English, this means that investors effectively get in on a business that holds £1 of assets for every 51p they invest!

Of course, this is the stock market where money is always at risk — these valuations can change and there are no guarantees. But some risks are a LOT more interesting than others, and at The Motley Fool we believe this company is amongst them.

What’s more, it currently boasts a stellar dividend yield of around 8.5%, and right now it’s possible for investors to jump aboard at near-historic lows. Want to get the name for yourself?

See the full investment case

More on Investing Articles

Investing Articles

0.45x EV-to-EBITDA: this is the cheapest UK stock, IMO

This UK stock has come under increasing pressure in recent weeks, but I don’t think it’s warranted. Here’s a closer…

Read more »

Investing Articles

Can the Rolls-Royce share price hit £13 in the coming year?

After a stunning couple of years for the Rolls-Royce share price, can it keep up its recent momentum? This writer…

Read more »

Calendar showing the date of 5th April on desk in a house
Investing Articles

Here’s how a £20k ISA could produce £1,580 of passive income in the next year

A Stocks and Shares ISA stuffed with dividend shares can be a lucrative source of passive income. Christopher Ruane explains…

Read more »

Investing Articles

Prediction: 12 months from now, £5,000 invested in Tesla stock could be worth…

Tesla stock has endured a miserable year so far, falling by 29%. Muhammad Cheema takes a look at how it…

Read more »

Investing Articles

See what £10,000 invested in Tesla shares at their mid-December peak is worth today 

As the world absorbs the full scale of Donald Trump's tariffs, Tesla shares are reeling. Investors who bought the stock…

Read more »

Hand flipping wooden cubes for change wording" Panic " to " Calm".
Dividend Shares

2 ‘safe’ LSE dividend stocks to consider as global markets sell off

As global markets experience high levels of volatility due to economic uncertainty, investors are piling into these ‘safe-haven’ dividend stocks.

Read more »

Investing Articles

US stock market rout: an unmissable opportunity for investors?

His tech-heavy portfolio has been smashed by Trump’s tariffs. However, Dr James Fox believes there could be some opportunities in…

Read more »

Investing Articles

After a 13% ‘Trump tariff’ fall, is the Barclays share price too cheap to miss?

Does the Barclays share price fall mean we should all panic and run screaming from the stock market? Nah, of…

Read more »